Through NIH funding, universities for decades have partnered with the federal government to support scientists' academic pursuits. Duke University pharmacology and cancer biology professor Donald McDonnell estimates his laboratory has received up to $40 million in NIH funding over 30 years. His lab developed a drug approved in 2023 by the U.S. Food and Drug Administration to treat metastatic breast cancer. Upkeep for lab equipment, including machines to grow cancer cells and massive freezers for enzymes and chemicals, would be difficult to afford if indirect cost rates dropped to 15%, McDonnell said. His laboratory also likely will be in the red due to the uncertainty around NIH grants, which would lead to staff layoffs. "The bottom line is, I can't live, I can't think in this chaos," McDonnell said.